• There are no suggestions because the search field is empty.

Anne-Sophie Grell

Manager Regulatory Affairs – Medical Devices | PhD in Physics | MSc in Medical Physics

Anne-Sophie Grell is a highly respected Regulatory Affairs leader with over two decades of multidisciplinary experience in medical physics, diagnostic imaging, and medical device regulation. At QbD Group, she supports clients navigating EU MDR, FDA, and international regulatory frameworks, especially for high-tech devices in radiology, radiotherapy, and proton therapy.

Biography

Anne-Sophie Grell holds a PhD in Physics (2001) and a Master’s in Medical Physics (2006). She began her career as a researcher and physics control lead in medical imaging at the Institut Jules Bordet, and quickly established herself as a trusted authority in radiology quality control and medical device compliance.

Her deep expertise earned her appointments as board member of the Belgian Association for Medical Physicists and effective member of the Belgian Federal Health Agency’s medical device evaluation commission. In 2010, she transitioned to the industry side, joining IBA as QA/RA Manager, and later RA Director, overseeing both medical and non-medical device portfolios.

At IBA, Anne-Sophie led global registration strategies and was instrumental in proton therapy upgrade projects. She later joined Philips IGTD as Senior RA Expert and APAC Regional Lead, managing submissions and market access across Russia, China, India, New Zealand, and more.

Since 2021, she has been Manager RA PD at QbD, where she leads regulatory strategies for X-ray, MRI, radiotherapy, and AI-powered imaging devices, with a strong focus on EU MDR, ISO 13485, ISO 14971, and global market registration.

Regulatory Affairs  Our Services - QbD Group

Anne-Sophie's key areas of expertise

Medical Imaging & Radioprotection

Physics control, quality assurance, and compliance strategies for X-ray, mammography, MRI, and radiotherapy devices.

EU MDR, FDA & Global Regulations

Extensive hands-on experience with EU MDR 2017/745, FDA 21 CFR Part 820, ANVISA, and regulatory pathways across Asia and Latin America.

Proton Therapy & High-Risk Device Registration

Proven track record of leading successful registrations for highly innovative and complex devices globally.

Technical Documentation & PRRC Expertise

Deep knowledge of regulatory dossier structure, PRRC responsibilities, and automated documentation systems.
an award concept with a life sciency background

Awards, Recognitions & Affiliations

  • Board Member, BHPA (2007–2010)
  • Expert in Medical Physics – FANC, 2007
  • Recognized expert in mammography screening – Belgian Ministry, 2010
  • RAPS Member (2010–2019, 2021–present)
  • ISO 13485 Internal Auditor – Certified by BSI
  • Member of Team PRRC (2022–present)

Explore our expert content

preview_image
Blog

Usability Testing and MDR: Managing Risk with the Human Factor

Under the EU Medical Device Regulation (MDR), usability is no longer a...
preview_image
Blog

In-Silico Testing & MDR: Smarter Evidence, Not Optional Evidence

In-silico testing — using computational modeling and simulation techniques —...
preview_image
Blog

Environmental Risk Assessment (ERA) in Drug Products: Understanding the New EMA Guideline Updates

Balancing human health, regulatory compliance, and environmental...
preview_image
Blog

Can IVDR Be Your Global Regulatory Compass for Market Entry?

The In Vitro Diagnostic Regulation (IVDR) in the EU is widely...
preview_image
Blog

eCTD Publishing: 10 Tips for a Smooth Submission Process

Over the past few decades, the pharmaceutical industry has seen a...
preview_image
Blog

ICH Draft Q3E Guideline on Extractables & Leachables Now Open for Consultation

This milestone represents a decisive step toward harmonizing international...
preview_image
Blog

Expanded eIFU Eligibility under EU Regulation 2025/1234

Expanded rules for electronic instructions for use (eIFUs) Effective:...
preview_image
Blog

FDA Deadline Update - Risk of nitrosamine drug substance-related impurity (NDSRI)

Key takeaways from the update: Confirmatory testing and risk evaluation must...
preview_image
Blog

4 key guidance documents released under the EU MDR and IVDR frameworks

MDCG 2025-5 clarifies essential aspects of IVD performance studies, including...
preview_image
Blog

Launch of the first phase of the COMBINE Project 1 pilot - "all-in-one” coordinated assessment

Sponsors can now submit a single application for trials involving both a...
overlay
Webinar - ATMP Supply Chain Navigating the Challenges and Exploring the Vein-to-Vein Strategy - QbD Group (2)

Don't miss the latest updates in life sciences

Circles_banner_short-1